ARCT - Arcturus Therapeutics Holdings Inc.
| Previous Close | 9.49 |
| Open | 9.46 |
| Bid | 9.58 x 1000 |
| Ask | 9.68 x 800 |
| Day's Range | 9.46 - 9.80 |
| 52 Week Range | 4.11 - 10.29 |
| Volume | 34,872 |
| Avg. Volume | 50,712 |
| Market Cap | 126.99M |
| Beta (3Y Monthly) | 2.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.19 |
| Earnings Date | Oct 1, 2019 - Oct 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
- GlobeNewswire•4 days ago
Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
- GlobeNewswire•9 days ago
Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference
SAN DIEGO, Calif., July 10, 2019 -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and.
- Zacks•18 days ago
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
- GlobeNewswire•22 days ago
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO, June 27, 2019 -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics.
- American City Business Journals•25 days ago
Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
- Zacks•29 days ago
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
- GlobeNewswire•last month
Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics$30.
- GlobeNewswire•last month
Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation
SAN DIEGO, June 13, 2019 -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development.
- GlobeNewswire•2 months ago
Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
SAN DIEGO, May 20, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and.
- Zacks•2 months ago
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -54.55% and 25.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update
SAN DIEGO, May 13, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of.
- ACCESSWIRE•4 months ago
Four Healthcare Stocks Getting a Boost on Thursday
CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.
- GlobeNewswire•4 months ago
Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results
SAN DIEGO, March 18, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of.
- GlobeNewswire•5 months ago
Arcturus Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 11, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•5 months ago
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today announced that it will reassume 100% global rights for its flagship asset, clinical development candidate ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. ARCT-810 was previously subject to a 50/50 collaboration between Arcturus and CureVac AG.
- GlobeNewswire•6 months ago
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
SAN DIEGO, Jan. 03, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•7 months ago
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced the nomination of its first development candidate, ARCT-810, to treat ornithine transcarbamylase deficiency (OTCD). OTCD is the most common urea cycle disorder. Urea cycle disorders are a group of inherited metabolic disorders that make it difficult for afflicted patients to remove toxic waste products, as proteins are digested. ARCT-810 is based on Arcturus’s propriety lipid library which utilizes the company's LUNAR® delivery platform to safely and effectively deliver OTC messenger RNA to liver cells.
- Simply Wall St.•7 months ago
Do Insiders Own Lots Of Shares In Arcturus Therapeutics Ltd. (NASDAQ:ARCT)?
Every investor in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- GlobeNewswire•7 months ago
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11
SAN DIEGO, Dec. 03, 2018 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•8 months ago
Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO, Nov. 07, 2018 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•8 months ago
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and development facility on Monday, with President and CEO Joseph Payne, San Diego Mayor Kevin L. Faulconer, board members and more than 80 employees and consultants in attendance at the event. The new San Diego facility is over 24,700 square feet, more than twice the size of their previous facility, and is designed to help Arcturus and its team continue development and commercialization of therapeutics for rare, infectious, fibrotic and respiratory diseases with significant unmet medical need.
- Simply Wall St.•9 months ago
Is Arcturus Therapeutics Ltd (NASDAQ:ARCT) A Financially Sound Company?
The direct benefit for Arcturus Therapeutics Ltd (NASDAQ:ARCT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
